Ultra-high resolution HLA genotyping and allele discovery by highly multiplexed cDNA amplicon pyrosequencing by Lank, Simon M et al.
 
Ultra-high resolution HLA genotyping and allele discovery by
highly multiplexed cDNA amplicon pyrosequencing
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Lank, Simon M, Brittney A Golbach, Hannah M Creager, Roger
W Wiseman, Derin B Keskin, Ellis L Reinherz, Vladimir Brusic,
and David H O’Connor. 2012. Ultra-high resolution hla
genotyping and allele discovery by highly multiplexed cdna
amplicon pyrosequencing. BMC Genomics 13: 378.
Published Version doi:10.1186/1471-2164-13-378
Accessed February 19, 2015 11:59:01 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10589781
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAMETHODOLOGY ARTICLE Open Access
Ultra-high resolution HLA genotyping and allele
discovery by highly multiplexed cDNA amplicon
pyrosequencing
Simon M Lank
1, Brittney A Golbach
1, Hannah M Creager
1, Roger W Wiseman
1, Derin B Keskin
2,3, Ellis L Reinherz
2,3,
Vladimir Brusic
2,3 and David H O’Connor
1,4*
Abstract
Background: High-resolution HLA genotyping is a critical diagnostic and research assay. Current methods rarely
achieve unambiguous high-resolution typing without making population-specific frequency inferences due to a
lack of locus coverage and difficulty in exon-phase matching. Achieving high-resolution typing is also becoming
more challenging with traditional methods as the database of known HLA alleles increases.
Results: We designed a cDNA amplicon-based pyrosequencing method to capture 94% of the HLA class I
open-reading-frame with only two amplicons per sample, and an analogous method for class II HLA genes, with a
primary focus on sequencing the DRB loci. We present a novel Galaxy server-based analysis workflow for
determining genotype. During assay validation, we performed two GS Junior sequencing runs to determine the
accuracy of the HLA class I amplicons and DRB amplicon at different levels of multiplexing. When 116 amplicons
were multiplexed, we unambiguously resolved 99%of class I alleles to four- or six-digit resolution, as well as 100%
unambiguous DRB calls. The second experiment, with 271 multiplexed amplicons, missed some alleles, but
generated high-resolution, concordant typing for 93% of class I alleles, and 96% for DRB1 alleles. In a third,
preliminary experiment we attempted to sequence novel amplicons for other class II loci with mixed success.
Conclusions: The presented assay is higher-throughput and higher-resolution than existing HLA genotyping
methods, and suitable for allele discovery or large cohort sampling. The validated class I and DRB primers
successfully generated unambiguously high-resolution genotypes, while further work is needed to validate
additional class II genotyping amplicons.
Keywords: HLA, Genotyping, Roche/454, Pyrosequencing, Galaxy, Tissue typing, Cellular immunity, Multiplexing
Background
The human leukocyte antigen (HLA) complex on the
short arm of chromosome 6 encodes the most poly-
morphic genes in the human genome, and is extensively
studied due to the central role its associated proteins play
in the etiology of infectious diseases, autoimmune disor-
ders, and organ transplantation outcomes [1-5]. The
“classical” HLA class I and II gene products are involved
in endogenous and exogenous antigen presentation
respectively, mediating adaptive immune responses to
pathogens and tissue transplants. As sequencing methods
of characterizing human genetic diversity have prolifer-
ated, the number of known classical HLA alleles has
exploded, with over 6,800 distinct variants described to
date, 1,633 of which were identified in 2010 alone [6]. The
majority of observed allele variants occur within the class
I genes HLA-A, -B and -C, as well as the class II DRB
genes. These highly polymorphic loci are the most com-
monly studied for their differential effects on directing
adaptive immunity [7,8]. The rapid proliferation of
reference alleles in the curated IMGT database demon-
strates that coding HLA polymorphism is vast, with
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hundreds of individual alleles. For instance, in May of
2011, four new HLA-A*02 alleles were described [9] with
a total of 334 protein-distinct alleles of this lineage
described to date.
Non-synonymous allelic variants of HLA gene pro-
ducts can bind distinct antigenic peptides [10,11],
be subject to differential regulation [12,13], and have
varied interactions with T-Cell Receptors [14], Killer
Immunoglobulin-like Receptors[15] and viral proteins
[16]. The direct link between HLA polymorphism and
various diseases is a subject of intensive investigation,
with hundreds of published studies every year. High-
resolution HLA typing (to the specific protein, rather
than the serological group level) can elucidate the differ-
ential consequences of small protein changes within an
allele family, such as the alleles B*57:02 and B*57:03,
which can differ by a single nucleotide yet lead to differ-
ential outcomes during HIV infection [17]. The ability to
type individuals at true high-resolution may uncover fur-
ther links between individual alleles and disease.
Traditional HLA typing methods are losing their effect-
iveness at accurately predicting high-resolution (four-
digit) genotype due to the large number of highly similar
alleles. Molecular sequence specific PCR (SSP) and
sequence specific oligonucleotide hybridization (SSO)
methods use unique sequence signatures to detect the
presence or absence of an allele; however, with more
alleles being described every month, many with only one
novel single nucleotide polymorphism (SNP), it is impos-
sible for SSP panels to rule out the presence of uncom-
mon but similar alleles. For higher accuracy, these
methods rely on an ever-greater number of reactions to
distinguish potentially related alleles, or use complemen-
tary methods to resolve ambiguities [18]. More sophisti-
cated (and expensive) sequence-based methods improve
resolution; however, even “gold-standard” commercial kits
fail to produce the entire coding sequence of individually
typed alleles. Allele ambiguity is an increasing problem as
many new alleles have been described with SNP variants
outside of the traditional exons examined by sequence-
based typing (SBT). This has led to the proliferation of
methods for imputing four-digit genotype from limited se-
quencing data by utilizing known allele frequencies in
various populations [19-21].
Traditional typing methods thus cannot always distin-
guish between highly similar alleles that may differ by a
single SNP within the amplification region (SSP and
SSO) or outside of it (SBT), and using allele frequency
to inform genotyping can lead to results biased against
rare variants. For the highly polymorphic HLA genes,
SBT (Sanger- or Roche/454-based) usually only interro-
gates the class I exons 2 and 3 (or 2, 3 and 4), and exon
2 for class II alleles [22,23]. While many typing kits and
software may appear to generate unambiguous results
with their methods, they do not consider alleles newly
added to recent IMGT database versions. Single SNP
differences between related alleles in the non-assayed
exons could have potential regulatory or immunologic
consequences, although few studies have examined such
correlations due to the difficulty of sequencing the add-
itional regions. In fact, when considering the current
database, many common HLA class I and class II alleles
(particularly the highly polymorphic DRB locus) remain
four-digit ambiguous with exon 2,3,4 typing (class I) and
exon 2 typing (DRB) [Table 1] and (Additional file 1:
Table 1). To date, full allele sequencing and genotyping
are rarely employed due to the associated cost of multi-
exon amplification and sequencing, and difficulty of
determining exon phase, particularly for the small, less
polymorphic 3’ exons.
Recently, we described a novel HLA class I genotyping
method (cSBT), utilizing a PCR amplicon that univer-
sally amplifies a 581 bp diagnostic template from cDNA,
encompassing all of exon 3 plus portions of exons 2 and
4 [24]. This method allows unprecedented throughput
for class I HLA typing (through the use of a single
Table 1 Four-digit ambiguous alleles with standard SBT
methods and cSBT
Class I exon 2, 3, 4 ambiguous to 4-digit (high freq)
Allele dbMHC freq
C*07:02:01/07:50 13.20%
C*04:01/04:09 N 11.40%
C*07:01/07:06/07:18 8.20%
C*08:01/08:22 4.90%
B*07:02:01/07:61 4.80%
B*35:01:01/35:42:01 4.50%
16 others variable
DRB Exon 2 Ambiguous to 4-digit (high freq)
Allele dbMHC freq
DRB1*11:01/11:100 6.60%
DRB1*14:01:01/14:54 4.10%
6 others variable
All cSBT ambiguous to 4-digit
Allele dbMHC freq
A*74:01/74:02 0.90%
C*07:04/07:11 1.70%
B*27:05/27:13 1.50%
DRB1*12:01:01/12:10 1.80%
“Gold Standard” Sanger sequence-based genotyping usually amplifies a
minimal number of exons per allele, resulting in a large number of ambiguous
allele calls. A non-inclusive list of commonly observed alleles with four-digit
ambiguity using exon-based typing methods is shown for class I (exon 2, 3, &
4) and DRB (exon 2) alleles. Also included is a list of all four allele
combinations predicted to be four-digit ambiguous using the expanded cSBT
method.
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distinguish class I exons 2 and 3 (the minimal require-
ments for novel allele discovery), producing statically
ambiguous genotyping results.
The primary aim of this study was to expanded the
area of sequence coverage using novel primer binding
sites in exons 1 and 7 of the HLA class I open reading
frame, pan-locus DRB primers, and preliminary use of
universal primers for the other class II loci (DRA, DPA,
DPB, DQA, and DQB) to unambiguously identify HLA
genotypes in large patient cohorts with unprecedented
resolution and throughput without relying on the use of
population-specific allele frequency inferences [20,23].
We also designed an open-source analysis workflow
for rapidly imputing high-resolution genotype. In the
process, several novel HLA alleles were identified and
validated with direct PCR Sanger sequencing. Thus, the
improved cSBT method allows rapid screening of large
cohorts for potential novel allele characterization. This
general approach will also be adaptable to improving
second- and third-generation sequencing technologies
that may allow longer amplicons to be completely
sequenced [25,26].
Results
HLA Class I primer design
Alignment of all described HLA class I alleles revealed
several conserved sequence regions suitable for design-
ing pan-locus amplification primers. In addition to pre-
viously described primer sites for a 581 bp diagnostic
cSBT amplicon [24], other sites in exons 1 and 7 of the
class I open reading frame were used to produce two
overlapping genotyping amplicons (HLA-1 andHLA-2)
of size 676 bp and 925 bp covering nucleotides 50–725
and 145–1069 respectively (Figure 1). We predicted the
resolution of the expanded assay in silico by aligning
3,665 class I alleles over the area of sequence coverage,
and found only three 4-digit allele pairs that are ambigu-
ous as of the version 3.4 IMGT database Table 1. Since
theamplicons capture over 90% of the coding sequence,
and the majority of new alleles are described only from
exon 2,3 or 2,3,4 sequence only we do not expect that
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Roche/454 “A” Adapter Key Multiplex ID Tag HLA Specific Sequence
HLA-2 Forward
HLA-1 Reverse
Roche/454 “A” Adapter Key Multiplex ID Tag HLA Specific Sequence
HLA-1 Forward
Roche/454 “B” Adapter Key Multiplex ID Tag HLA Specific Sequence
HLA-2 Reverse
CGTATCGCCTCCCTCGCGCCA  TCAG   ACGAGTGCGT  GTGGGCTACGTGGACGAC         
CGTATCGCCTCCCTCGCGCCA  TCAG  ACGAGTGCGT   TGCCAGGTCAGTGTGATCTC
CTATGCGCCTTGCCAGCCCGC  TCAG  ACGAGTGCGT  TGGCCCTGACCSAGACCTG
CTATGCGCCTTGCCAGCCCGC  TCAG  ACGAGTGCGT     CAGAGCCCTGGGCACTGT
Roche/454 “B” Adapter Key Multiplex ID Tag HLA Specific Sequence
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Figure 1 Positioning and sequence of HLA class I universal amplification primers. An alignment of >4,000 known HLA class I alleles
produced a variability profile. (a) The depth of coverage (i.e. the number of alleles at each position in the alignment) is shown in grey, along with
the percentage of nucleotide sequence variability (red) and the positioning of the two genotyping amplicons. (b) The sequence and composition
of universal amplification primers for amplicon 1 and 2. Note that for amplicon 1 the “A” and “B” adapters were swapped to avoid a primer
amplification problem.
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ically increase with newer database versions.
HLA Class II primer design
We applied the same method to all HLA class II loci to
identify universal amplification primers. For the class II
DRB locus (the most polymorphic class II gene) primers
at positions 61–79 and 707–727 generated a 667 bp
amplicon (Figure 2) that is universally conserved, except
for auxiliary DRB3 alleles, which contain a single nucleo-
tide mismatch in the 5’ primer (C74G). Similar to the
class I alignment, in silico analysis of 966 DRB alleles
identified only a single 4-digit ambiguous allele combin-
ation Table 1. Using identical methods we also identified
preliminary universal primers for the other class II loci
DRA, DPA, DPB, DQA and DQB (Additional file 1:
Table 2).
Library preparation and pyrosequencing
We generated cDNA from total cellular RNA, and PCR-
amplified the three primary diagnostic HLA amplicons
described above (HLA-1, HLA-2 and DRB) from 98
separate samples, including 40 International Histocom-
patibility Working Group reference cell lines [http://
ihwg.org]. For a limited set of four reference samples we
also generated amplicons from the additional class II
loci. The quality and purity of the DNA amplicon
sequencing library is important to ensure successful
sequencing [27], so we performed multiple solid-phase
reversible immobilization (SPRI) clean-ups on our sam-
ples to remove excess primer-dimer and shorter PCR
products. We used 96 distinct multiplex identifier
(MID)-tagged primer pairs for each amplicon to gener-
ate sequencing libraries Additional file 1: Table S3.
The presence of differently sized amplicons in the
sequencing library is an important consideration. The
final amplicon sizes of the primary products (including
MIDs and adapter sequences) were 746 bp (HLA-1),
995 bp (HLA-2), and 737 bp (DRB Amplicon). Although
HLA-2 is longer than typically recommended for Roche/
454 pyrosequencing, the use of an augmented pooling
strategy accounting for the differential sizes of amplicons
(longer products at a higher molar ratio than the shorter
ones) produced normalized sequence data. This was
necessary since the Roche/454 emPCR process preferen-
tially amplifies shorter PCR products.
We attempted to sequence these amplicons over the
course of two Roche/454 GS Junior sequencing runs to
test the performance of the three amplicons and the
multiplexing limit of the Roche/454 GS Junior for our
assay respectively. Both sequencing runs performed well,
yielding a variable number of sequence reads depending
DRB Forward
Roche/454 “A” Adapter Key Multiplex ID Tag HLA Specific Sequence
DRB Reverse
CGTATCGCCTCCCTCGCGCCA  TCAG  ACGAGTGCGT  GTGCTGAGCTCCCSACTGG 
CTATGCGCCTTGCCAGCCCGC  TCAG  ACGAGTGCGT  CAAGGAAGAGCAGGCCCAGCA
Roche/454 “B” Adapter Key Multiplex ID Tag HLA Specific Sequence
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Figure 2 Positioning and sequence of HLA DRB universal amplification primers. An alignment of all known HLA DRB alleles produced a
variability profile. (a) The depth of coverage (i.e. the number of alleles at each position in the alignment) is shown in grey, along with the
percentage of nucleotide sequence variability (red) and the position of the DRB genotyping amplicon. (b) The sequence and composition of
universal amplification primers for the DRB amplicon
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ance of each amplicon at the augmented pooling ratios
Table 2 and Additional file 1: Table S4. A third sequen-
cing experiment of the additional class II amplicons gen-
erated a large number of reads per amplicon due to the
low multiplexing ratio Additional file 1: Table S5.
Analysis design and implementation overview
Traditional, genomic-sequence-based HLA analysis pipe-
lines and software tools are inadequate forcDNA amplicon
sequencing data sets [23,28]. To facilitate rapid analysis of
each de-multiplexed data set we designed a standardized
workflow, using Galaxy server [29] to map individual
reads to the set of reference alleles (3,665 class I, 996
DRB) using the BLAT alignment tool [30]. An overview
schematic of the mapping strategy Figure 3 a and b as well
as the specific Galaxy workflow are available. The work-
flow can be ported to any Galaxy instance with the neces-
sary tools installed, including UNIX tools (http://
hannonlab.cshl.edu/galaxy_unix_tools/index.html) and a
custom Perl tool Additional file 2: File 1.
The different length of HLA reference alleles relative
to the sequence positions necessitates an iterative ap-
proach to determining genotypes. To improve data regu-
larity and quality, all reads were subjected to stringent
length filtering and trimming (between 300 and 350 bp
trimmed reads, depending on the amplicon), which
resulted in the loss of 25% to 60% of total filterpass
sequences. The remaining normalized sequence reads
were mapped at 100% identity to reference alleles, and
the pattern and number of sequence matches for each
individual was evaluated to deduce genotype.
For samples that sequenced or amplified at lower
numbers, and for our second highly multiplexed experi-
ment, we employed a less stringent, modified pipeline
that allowed allele-specific read groups of any number.
These calls are noted in orange on the genotyping tables
and are of intermediate confidence due to the limited
number of sequencing reads.
Class I genotyping analysis
For class I genotyping, allele mapping began with the
HLA-2 forward reads (2 F) to determine the constella-
tion of potential alleles present in an individual
Figure 3c. This was possible since trimmed 2 F reads en-
compass only part of exons 2 and 3, and all named
alleles have complete exon 2 and 3 sequences. Perfectly
matched 2 F reads thus dictated the reference set for
subsequent matches, reducing the number of alleles
evaluated for subsequent mapping from several thou-
sand to several hundred and dramatically decreasing
computation time for subsequent BLAT mapping.
Using this restricted subset of reference alleles, the
other trimmed read groups were evaluated for identity.
Based on the positioning of these reads relative to the
reference, we established match conditions for each
potential allele. These conditions included fully matched
reads (condition #1), partially matching reads where the
query read contained nucleotide positions not known for
the reference, such as exon 1 sequence for exon 2/3-only
alleles (condition #0), and unmatched reads (condition
null). For alleles of different lengths, a distinct matrix of
read match conditions is expected Figure 3d. The matrix
is generated by performing inner joins of the 2 F dataset
to the 1 F and 1R matches, and an outer join with the
2R matches to account for short reference alleles with
null 2R match conditions.
Class II genotyping analysis
For class II data, the same length and quality filtering were
applied, and similar issues arose when mapping the for-
ward and reverse reads, as many alleles are known only
from exon 2 sequence. In this case forward reads are used
as the key to limit the potentially matching allele set, con-
sidering matches with extension sequences at both the 5’
and 3’ end valid due to the positioning of the reads relative
to exon 2. Reverse reads are then evaluated against a refer-
ence subset of only forward matching alleles. A condition
matrix, similar to the one used for class I reads, is estab-
lished. However, due to the prevalence of exon-2-only
reference alleles, an additional condition is added for
forward reads when the query reads contain additional
5’and 3’ sequence relative to the reference.
Class I genotyping results
The first genotyping experiment produced high-
resolution class I allele calls that were 99% concordant
to four- or six-digit resolution with previous typing
Figure 4. The majority of alleles were typed to six-digit
resolution (209 of 224 calls), and most of the remaining
Table 2 Read metrics for both sequencing runs described
Run 1 Run 2
Raw Wells 194,989 220,452
Keypass Wells 193,002 218,741
Filterpass Wells 74,101 77,977
Ave Length (st. dev) 482 (108) 487 (91)
Samples Multiplexed 52 92
Amplicons Multiplexed 116 271
Reads per Sample (st. dev) 1,319 (520) 825 (504)
Amp 1 Reads per Sample (st.dev) 542 (167) 386 (142)
Amp 2 Reads per Sample (st. dev) 592 (272) 352 (247)
DRB Reads (st. dev) 803 (378) 92 (79)
The number of raw, keypass, and filterpass reads per run are shown, along
with the number of samples multiplexed, and the average read number for
each amplicon included in the pool.
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Exon 1 - 7 1 1 1 1
Exon 1 - 4 1 1 1 0
Exon 1 - 3 1 1 0 .
Exon 2 - 4 0 1 1 0
Exon 2 - 3 0 1 0 .
“1F” Reads “1R” Reads
“2F” Reads “2R” Reads
Galaxy (Class I)
Sequence cleanup & trimming
Align “2F”  sequences (BLAT)
to ALL HLA Class I alleles
100% Identity Alleles
Read direction parsing
Align “1F” 
Sequences (BLAT)
Align “1R” 
Sequences (BLAT)
Align “ 2F” 
Sequences (BLAT)
Group perfect
match alleles
Join grouped
matches (matrix
match table)
Filter incorrect
matrix match
types
Report HQ,
rows
Galaxy (DRB)
Sequence cleanup & trimming
Align “ F” Sequences (BLAT)
to ALL DRB alleles
Read direction (amplicon) parsing
Align “R” Sequences (BLAT)
Join grouped
matches (matrix
match table)
Filter incorrect
matrix match
types
Group perfect
match alleles
Group perfect
match alleles
100% Identity Alleles
Group perfect
match alleles
Report HQ,
rows
Read positions relative to exons & alleles
Exon 1 Exon 2 Exon 3 Exon 4 E6 E7
Amplicon 
Reads
Reference 
Alleles
n = 448
n = 3,439
n = 831
n = 54
n = 442
Exon 2 - 3 Alleles
Exon 1 - 3 Alleles
Exon 2 - 4 Alleles
Exon 1 - 4 Alleles
Exon 1 - 7 Alleles
HLA-1
HLA-2
Expected Allele Match Matrix
a. b.
c.
d.
Exon 5
Figure 3 Overview of mapping pipeline using Galaxy server, and generation of an expected allele match matrix. Our Galaxy-based
mapping pipeline is shown for both class I (a) and DRB (b) sequence reads. The parsed “2F ” reads are used to limit the subset of subsequent
alleles for matching since all named class I alleles have 2 F sequences as shown (c). The expected allele match matrix is shown for class I alleles
(d). Type 1 matches are full, 100% identity matches along the entire read length. Type 0 are partial matches, where the read is longer than the
reference allele (and contains novel sequence). Null matches (.) indicate no expected read match based on the lack of a reference allele
sequence.
Lank et al. BMC Genomics 2012, 13:378 Page 6 of 13
http://www.biomedcentral.com/1471-2164/13/378four-digit high-resolution calls did not have any asso-
ciated alleles with six-digit distinctions, and are still
considered to be allele-specific matches. One allele
(C*17:01:01 from HIV_114) was only detected with the
lower stringency, modified analysis pipeline described
above. Another allele (B*18:01:01:01 from HLA-Ref20)
did not amplify in amplicon 2 due to a single bp forward
primer mismatch, accounting for the 1% lack of concord-
ance with previous typing data. In this case, the allele
was detected in HLA-1 sequences, but was missed with
the analysis pipeline due to the lack of HLA-2 matches.
A small number of samples failed to amplify due to
MID Sample 
Name 
A1 A2  B1  B2  C1  C2 
1 HIV_106  02:01:01  29:02:01  40:01:02  44:03:01  03:04:01  16:01:01 
2  HIV_107  30:02:01  68:01:01  27:05:02 / 
27:13 
01:02:01  05:01:01 
3 HIV_110  01:01:01:01  02:01:01  44:02:01:01  52:01:01  05:01:01  12:02:02 
4 HIV_111  01:01:01:01  11:04  08:01:01  44:03:02  07:01:01  07:06 
5 HIV_112  03:01:01  31:01:02  07:02:01  07:02:01 
6 HIV_113  11:01:01  30:01:01  13:02:01  58:01:01  03:02:02  06:02:01 
7 HIV_114  36:01  68:01:01  41:02:01  53:01:01  04:01:01  17:01:01 
8 HIV_115  03:01:01  11:01:01  07:02:01  51:01:01  07:02:01  15:02:01 
9 HIV_116  01:01:01  02:01:01  08:01:01  15:01:01  03:04:01  07:01:01 
10 HIV_117  26:01:01  29:02:01  44:03:01  44:10  04:01:01 
11 HIV_118  02:01:01  23:01:01  40:01:02  44:03:01  03:04:01  14:03 
12 HIV_119  29:01:01:01  68:01:02  07:05:01  44:02:01  05:01:01  15:05:01/02 
35 HIV_121  02:01:01  11:01:01  07:02:01  51:01:01  01:02:01  07:02:01 
37 HIV_122  29:02:01  32:01:01  14:01  37:01:01  06:02:01  08:02:01 
13 HLA-Ref01 31:01:02  51:01:01  15:02:01 
14 HLA-Ref02 32:01:01  38:01:01  12:03:01 
15 HLA-Ref03 02:16  03:01:01  51:01:01  07:04:01 / 07:11  15:02:01 
16 HLA-Ref04 24:02:01  26:02  40:06:01  51:01:01  08:01:01  14:02:01 
17 HLA-Ref05 30:01:01  13:02:01  06:02:01 
18 HLA-Ref06 02:01:01  02:07  46:01:01  01:02:01 
19 HLA-Ref07 33:03:01  44:03:01  14:03 
20 HLA-Ref08 30:01:01  68:02:01  42:01:01  17:01 
21 HLA-Ref09 02:06:01  11:01:01  15:01:01:01  35:01:01  03:03:01  04:01:01 
22 HLA-Ref10 26:01:01  08:01:01  07:01:01 
23 HLA-Ref11 02:04  51:01:01  15:02:01 
24 HLA-Ref12 03:01:01  47:01:01  06:02:01 
26 HLA-Ref14 02:01:01  35:03:01  12:03:01 
27 HLA-Ref15 02:01:01  35:01:01  04:01:01 
28 HLA-Ref16 34:01:01  15:21  15:35  04:03  07:02:01 
29 HLA-Ref17 02:01:01  15:01:01:01  03:04:01 
30 HLA-Ref18 01:01:01:01  49:01:01  07:01:01 
31 HLA-Ref19 25:01:01  51:01:01  01:02:01 
32 HLA-Ref20 30:02:01  18:01:01:01  05:01:01 
33 HLA-Ref21 01:01:01:01  02:05:01  08:01:01  50:01:01  06:02:01  07:01:01 
34 HLA-Ref22 01:01:01:01  03:01:01  07:02:01  58:01:01  07:02:01  07:18 
38 HLA-Ref26 03:01:01  07:02:01  35:01:01  04:01:01  07:02:01 
39 HLA-Ref27 03:01:01  07:02:01  35:01:01  04:01:01  07:02:01 
40 HLA-Ref28 01:01:01:01  03:01:01  35:01:01  58:01:01  04:01:01  07:18 
41 HLA-Ref29 03:01:01  24:02:01  35:01:01  51:01:04  04:01:01  07:04:01 / 07:11 
42 HLA-Ref30 02:01:01  03:01:01  07:02:01  37:01:01  06:02:01  07:02:01 
43 HLA-Ref31 01:01:01:01  24:02:01  39:06:02  58:01:01  07:01:01  07 novel (C1045T) 
45 HLA-Ref33 03:01:01  07:02:01  35:01:01  04:01:01  07:02:01 
46 HLA-Ref34 03:01:01  24:02:01  35:01:01  39:06:02  04:01:01  07:02:01 
47 HLA-Ref35 02:01:01  24:02:01  07:02:01  13:02:01  06:02:01  07:02:01 
48 HLA-Ref36 24:02:01  31:01:02  07:02:01  40:01:02  03:04:01  07:02:01 
49 HLA-Ref37 02:01:01  24:02:01  15:01:01:01  39:06:02  03:03:01  07:02:01 
52 HLA-Ref40 02:01:01  29:02:01  35:01:01  44:03:01  04:01:01  16:01:01 
Figure 4 The HLA class I allele calls from the first genotyping experiment, designed to test the use of the two-tiled class I amplicons,
are shown. Calls in blue were completely unambiguous to the allele level. Calls in green were four-digit ambiguous based on distinguishing
SNPs outside the amplified region. The call in orange was only recovered using the modified, lower-stringency analysis pipeline, while the call in
pink was expected but not observed for both amplicons. Calls in purple were examples of reference typing undergoing correction, or the
detection of a putative novel allele.
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results [data not shown].
Our attempt to push the assay to 92 samples (271
amplicons, both class I and DRB) in a single GS Junior
run for the second experiment missed many alleles (not
seen, rather than incorrectly called) without using the
modified, lower-confidence pipeline. Still, at this multi-
plexing level our assay yielded high-resolution, accurate
genotyping for 93% of expected class I alleles (Additional
file 1: Table S6).
Our sequence-based results overturned several incorrect
typings in the reference samples that were subsequently
confirmed with traditional typing methods. With the
additional exon coverage in this experiment, we were able
to demonstrate deficiencies in the original SSOP reference
cell line typing. This included correcting the original
HLA-C*07:01 calls for samples HLA-Ref22 andHLA-
Ref28 to HLA-C*07:18. The distinguishing SNP between
these alleles occurs at nucleotide 1043, and was not
assayed with either previous SSP or SBT methods. We
also identified a putative novel HLA-C*07 allele in sample
HLA-Ref31.
Class II genotyping results
The first experiment applied the DRB amplicon to
unknown patient samples as part of a separate study,
rather than the HLA reference samples. However, we
identified two DRB1 unambiguous, high-resolution allele
calls for all 12 samples as expected (Figure 5), as well as
a number of DRB3, 4, and 5 high-resolution calls. In the
second, highly-multiplexed experiment (which included
class I and DRB amplicons for each sample) expected
DRB alleles were occasionally missed (similar to the
class I results). However, the accuracy of the DRB calls
with the lower confidence pipeline resulted in 96%
accuracy for DRB1 alleles, and 84% for additional DRB
loci alleles, in addition to identifying three putative novel
alleles (Additional file 1: Table S7). Considering this
data, as well as DRB allele calls in the second experi-
ment, which used the reference samples, the DRB ampli-
con appears to be successful at establishing correct
DRB1 genotypes and of undetermined efficacy for other
DRB locus calls at the higher multiplexing levels.
In the third experiment of additional class II loci ampli-
cons we identified alleles from each locus sequenced for
all four samples Additional file 1: Table S8. Comparison of
this data with the reference class II typing previous done
on the samples by SSOP was 72% concordant (13 of 18
alleles matching). However, in several cases our results
were discordant with original typing, either identifying
different variants of the same serological group, or identi-
fying alleles not seen with SSOP typing. It is unclear
whether these differences result from our analysis meth-
ods or further deficiencies in the SSOP reference typing,
as was the case for several class I alleles in the other
experiments.
Novel allele characterization
As a demonstration of the ability of the assay to detect
novel alleles, we chose one of the putative novel
sequences (Additional file 3: File 2) identified in sample
KTS02 and confirmed its sequence using allele-specific
PCR and Sanger sequencing. All alleles present in KTS02
were interrogated, and primers specific for the putative
novel allele were identified. Following primary PCR,
six allele-specific primers were used to Sanger sequence
this product (Additional file 1: Table S9). Analysis of the
resultant data confirmed the novel SNP (T587C), result-
ing in a proline to leucine substitution. This sequence
was submitted for approval and the name HLA-C*08:56
was officially assigned by the WHO Nomenclature Com-
mittee in October 2011. This follows the agreed policy
that, subject to the conditions stated in the most recent
Nomenclature Report that names will be assigned to new
sequences as they are identified [31]. Lists of such new
names will be published in the following WHO Nomen-
clature Report.
Discussion
We present an improved version of a previously
described cSBT assay with dramatic improvements in
resolution through the use of additional universal primer
binding sites in the HLA class I open reading frame, the
addition of a universal DRB amplicon, and preliminary
data from additional class II loci amplicons. Our results
demonstrate a scalable technique for use on either the
Roche/454 GS Junior or the FLX platform with Titanium
chemistry.
The use of a cDNA template, combined with clonal
second-generation pyrosequencing, allows comprehen-
sive genotyping from only two PCR amplifications for all
HLA class I loci, instead of the nine or more exon- and
locus-specific amplifications required for genomic DNA
template methods (both Sanger and Roche/454-based).
Other amplicons, such as those presented for DRB and
other class II loci, can be used to achieve high-resolution
genotyping as needed. This updated method allows for
dozens or hundreds of patient samples to be HLA class I
(and DRB or other loci) genotyped to true high-
resolution (allele-specific) simultaneously using fewer
amplicons per sample, at a low per-sample cost for both
large scale screening projects (1,000 s of samples) using
a GS-FLX instrument, or smaller (dozens to hundreds of
samples) on a GS Junior instrument. Per-sample cost
varies depending on the level of multiplexing and other
factors, but can be estimated at~$70 - $100 for a 48 to
96 sample multiplexed experiment on a GS Junior
instrument (Additional file 1: Table S10). Our results
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   DRB1  DRB1  DRB3  DRB3  DRB4  DRB4  DRB5  DRB5 
HIV_106  03:01:01  15:01:01  01:01:02  01:01:01 
HIV_107  01:01:01  04:04:01  01:03:01:01 
HIV_110  04:01:01  15:02:01  01:03:01:01  01:02 
HIV_111  03:01:01  07:01:01  01:01:02  01:03:01:01 
HIV_112  13:01:01  15:01:01  01:01:02  01:01:01 
HIV_113  07:01:01  15:01:01  01:01:01 
HIV_114  01:02:01  16:02:01  02 novel (A694G) 
HIV_115  04:04:01  07:01:01  01:01:01:01  01:03:01:01 
HIV_116  03:01:01  04:01:01  01:01:02  01:03:01:01 
HIV_117  03:01:01  07:01:01  02:02:01  01:03:01:01 
HIV_118  04:01:01  10:01:01  01:03:01:01 
HIV_119  04:04:01  07:01:01  01:03:01:01 
Run  #2 (271 sample multiplex)
   DRB1  DRB1  DRB3  DRB3  DRB4  DRB4  DRB5  DRB5 
HIV 106  03:01:01  15:01:01  01:01:02  01:01:01 
HIV 107  01:01:01  04:04:01  01:03:01:01 
HIV 110  04:01:01  15:02:01  01:03:01:01  01:02 
HIV 111  03:01:01  07:01:01  01:01:02  01:03:01:01 
HIV 112  13:01:01  15:01:01  01:01:02  01:01:01 
HIV 113  07:01:01  15:01:01  01:01:01 
HIV 114  01:02:01  16:02:01  02 novel (A694G) 
HIV 115  04:04:01  07:01:01  01:01:01:01  01:03:01:01 
HIV 117  03:01:01  07:01:01  02:02:01  01:03:01:01 
HIV 118  03:01:01  10:01:01  01:03:01:01 
HIV 119  04:01:01  07:01:01  01:03:01:01 
HLA-Ref01  04:07:01  01:03:01:01 
HLA-Ref02  11:01:01  02:02:01 
HLA-Ref03  11:04:01  12:01:01  02:02:01 
HLA-Ref04  09:01:02  01:03:02 
HLA-Ref08  03:02:01 
HLA-Ref09  04:03:01  04:06:01  01:03:01:01 
HLA-Ref10  15:01:01  01:01:01 
HLA-Ref11  16:02:01  02:02 
HLA-Ref12  07:01:01  01:01:01:01 
HLA-Ref15  08:01:03 
HLA-Ref16  04:05:01  08:03:02 
HLA-Ref17  04:04:01  01:03:01:01 
HLA-Ref18  11:02:01  02:02:01 
HLA-Ref19  04:04:01  01:03:01:01 
HLA-Ref20  03:01:01  02:02:01 
HLA-Ref21  03:01:01  07:01:01  01:01:02 
HLA-Ref22  08:01:03  13:03:01  01:01:02 
HLA-Ref26  14:54  08:01:03  02:02:01  03:01 
HLA-Ref27  08:01:03  14:54  02:02:01  03:01 
HLA-Ref28  13:03:01  14:54  01:01:02  02:02:01 
HLA-Ref29  14:54  16:01:01  02:02:01  03:01  01:02  02:02 
HLA-Ref30  08:01:03  10:01:01 
HLA-Ref31  08:01:03  13:03:01  01:01:02 
HLA-Ref33  08:01:03  14:54  02:02:01  03:01 
HLA-Ref34  08:01:03  14:54  02:02:01 
HLA-Ref35  04:04:01  07:01:01  01:03:01:01 
HLA-Ref36  04:04:01  01:03 
HLA-Ref37  08:01:03  11:03  02:02:01  03:01 
Figure 5 (See legend on next page.)
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higher resolution than existing methods, and does not
rely on population-specific allele frequency inferences.
Higher throughput than reported here (>92 samples
typed at a time) is possible for the entire pre-emPCR
process in a lab setting utilizing liquid handling robotics
for RNA extraction, cDNA synthesis, PCR amplification,
SPRI purification, quantification, and pooling, similar to
the methods employed by Erlich et al. [23]. Despite the
need to generate 288 amplicons per 96 samples typed
with the cSBT method for class I and DRB loci, this is a
dramatic reduction over the >960 amplicons needed to
perform comparably accurate typing from genomic
DNA starting material using locus- and exon-specific
amplification primers [22,23,28].
An important caveat to the presented data is the dif-
ferent levels of multiplexing used in the first two geno-
typing experiments. This limited data is insufficient to
establish an “ideal” multiplexing level for cSBT. The
first GS Junior sequencing run, which multiplexed 116
amplicons (equivalent to 58 class I samples, 39 class I+
DRB, or 15 class I+all class II loci) was highly accur-
ate, and is the current recommended multiplexing
level. Investigators who consistently recover abundant
data may wish to increase the multiplexing level nearer
to the second sequencing run (271 amplicons multi-
plexed), which, in the presented data, performed nearly
as well as the lower multiplexed run when lowering
sequence number requirements.
Another consideration is the use of and availability of
high-quality RNA, which is necessary for cSBT. Trad-
itionally, HLA typing facilities have collected DNA for
use with established assays. DNA has the advantage of
being easier to collect and store, whereas RNA requires
more robust preservation and extraction methods. The
limited access to RNA may not make cSBT ideal for all
situations, particularly clinical settings that only have ac-
cess to poor-quality starting material. In such cases a
genomic DNA-based method may be more appropriate
[22][23]. Current studies, underway with collaborators,
are evaluating the use of saliva, buccal swabs, or tissue
biopsies as RNA starting material. Initial results with
saliva starting material have led to successful amplicon
generation. However, class II genotyping likely requires
the use of whole blood or PBMC as a starting material,
since class II transcripts are unlikely to be expressed in
other tissues.
This general approach will be adaptable to improving
second- and third- generation sequencing techniques
that may allow even longer amplicons to be completely
sequenced [25,26]. As longer read-length clonal sequen-
cing technologies become available (such as GS-FLX+
from Roche/454 or SMRT sequencing from Pacific
Biosciences), it should be possible to use the exon 1 and
exon 7 primer sites described here to amplify a single
PCR product, instead of the two tiled amplicons that are
required currently. We have already successfully ampli-
fied and sequenced this ~1 kb amplicon with Roche/454
Titanium sequencing, although the high-quality read
lengths were insufficient to provide complete coverage
(data not shown). However, the use of a single amplicon
increases the likelihood that a subset of alleles with pri-
mer incompatibilities could be missed, since a two-tiled
amplicon approach produces redundant data with two
separate amplifications. Using two class I amplicons acts
as an important control to ensure that any allele with
primer incompatibilities for a given amplicon is detec-
ted with the other, such as the detection of HLA-
B*18:01:01:01 in sample HLA-Ref20 despite a primer
mismatch for one of the amplicons. In our highly-
multiplexed experiment, the loss of one amplicon read
direction was more common, even for non-mismatched
alleles, and this impacted our ability to distinguish allele
resolution, though we were still able to detect signatures
of alleles missing from a single read group. The use of a
second class I amplicon also facilitates analysis of appar-
ently homozygous loci, which can be artifacts of poorly
amplified or potentially novel alleles. It should be noted
that although the sequencing platform and read length
may change, the cSBT primers and much of the analysis
methods presented here would be applicable to any
cDNA-based assay.
Methods with more limited coverage than cSBT can
lead to incorrect genotype associations. For instance, in
our reference panel we were able to determine that two
allele calls originally labeled as HLA-C*07:01 were in
fact HLA-C*07:18, which encodes a distinct protein.
This underscores the power of our approach, which does
not assume ambiguously amplified sequences to be the
most likely allele in a given population. Additionally, our
genotyping results were usually accurate to six-digit
resolution, an unprecedented achievement for a high-
throughput HLA genotyping assay. While it is currently
unknown whether synonymous coding six-digit variants
(See figure on previous page.)
Figure 5 The resolution and accuracy of the DRB genotyping amplicon in both experiments for HIV patient samples and known
reference samples. Calls in blue were completely unambiguously detected. Calls in orange were detected using the modified, lower-stringency
Galaxy pipeline, calls in purple were novel or corrected reference alleles. Calls in yellow were observed in some, but not all of the read directions
(typically missed in the 2R read direction) and cannot be considered completely assayable at the indicated multiplexing level. The full DRB
genotyping results (including non-reference samples) for the second experiment can be found in Additional file 1: Table S5.
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correlations, it should now be possible to examine this
question.
Our preliminary investigations into typing other class
II loci have show that the presented primers generate
sequencable products, which map to known alleles.
However, more work is needed to validate these ampli-
cons properly as we have not determined the cause of
observed differences between reference SSOP typing and
the presented cSBT typing. We provide this data, and
the primers used, so that investigators can carry out
further work on these loci if desired.
Two other potential applications of expanded cSBT
are novel allele discovery and extending the reference se-
quence length of known alleles. In the first case, we have
shown that cSBT can effectively screen large cohorts for
novel alleles, which can then be characterized with trad-
itional and accepted sequencing methods. In the second
application, the majority of named HLA class I alleles
are known only from exon 2 and 3 sequence (3,439
alleles). Thus, if cSBT was applied to samples with these
rare alleles, exons 4, 5, and 6 and parts of exons 1 and 7
could be quickly deduced to improve the length and
quality of the IMGT reference database.
Conclusions
The rapidly expanding number of described classical
HLA alleles is undermining the utility of previously un-
ambiguously high-resolution typing assays to provide
unambiguous results. The cSBT method presented here
offers one solution to overcome the difficulties asso-
ciated with the ever-expanding HLA allele library:
sequence a larger fraction of the open reading frames,
and use cDNA starting material to eliminate the pro-
blems of exon-phase matching. Combining this with
clonal, long-read-length Roche/454 pyrosequencing has
produced the ability to unambiguously resolve alleles
for large cohorts at a fraction of the cost and time of
previous methods. This method also does not rely on
population-specific allele frequency inferences, and only
uses the a priori knowledge of the conserved primer
binding sites to amplify both known and novel alleles.
The modified cSBT method for high-throughput, high-
resolution HLA typing should accelerate studies involv-
ing large cohort genotyping, and allow a deeper survey
of worldwide HLA polymorphism in historically under-
studied regions [32].
Methods
Samples used
Human cell line or patient-derived cellular RNA was
collected from a variety of sources and in accordance
with the University of Wisconsin and Dana Farber
Cancer Research Center’s policy on human research
subjects. Samples were anonymized prior to typing, and
no genotyping results were released to physicians or
used to inform clinical treatments. Samples were pro-
cessed for RNA either as cell pellets, cell-culture homo-
genates, peripheral blood mononuclear cells, or whole
blood. Samples included 15 patient samples from an un-
related HIV study at the University of Wisconsin, 40
HLA reference cell lines provided by the International
Histocompatibility Working Group, 5 human embryonic
cell-lines provided by WiCell, 40 samples derived from
cell-lines or patients collected by the Dana Farber Can-
cer Center, and 10 blood samples from female Korean
patients with HPV-16-induced cervical cancers from an
unrelated study [33].
RNA isolation and cDNA synthesis
Methods for isolation of RNA and cDNA synthesis were
identical to those presented previously [24], involving
the MagaNA Pure LC RNA isolation platform (Roche
Applied Science, Indianapolis, IN), quantification using a
NanoDrop 1000 spectrometer (ThermoFisher, Waltham,
MA) and oligo(dT)20-primed SuperScript III cDNA syn-
thesis (Invitrogen, Carlsbad, CA). For all experiments an
input of 50 ng RNA was used to seed the cDNA
synthesis.
Universal primer design
The design of the 581 bp internally diagnostic amplicon
has been previously described [24]. The method for find-
ing additional conserved sites for HLA class I and HLA
DRB universal primers was similar, and is briefly
described here. All known HLA class I and DRB refer-
ence sequences from the IMGT/HLA database were
aligned using MUSCLE [34] or CodonCode Aligner
(CodonCode Corporation, Dedham, MA). All analysis
was done with IMHT/HLA Release 3.4 (April 2011) [6].
In addition to the previously described HLA class I
581 bp amplicon spanning consensus positions 145–725
[24] we identified novel conserved primer binding sites
in exons 1 and 7. Due to current read length limitations
of GS-FLX Titanium reagents we could not fully se-
quence this amplicon. However, by combining this
1020 bp amplicon with the 581 bp amplicon acting as a
bridge, we were able to tile nucleotides 50–1069 of the
HLA class I open reading frame, including all of exons 2
through 6. To further normalize the distribution of
reads, we altered these original 581 and 1 kb amplicons
by mixing their forward and reverse primers. The class
II DRB and other loci genotyping amplicon was identi-
fied with similar methods.
Initial sequencing with the HLA-1 forward primer
revealed a sequence incompatibility with most HLA-A
alleles, leading to the generation of a short, chimeric DNA
bead which interfered with genotyping Additional file 4:
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454 adapter positions, using adapter “B” with the forward
gene-specific primer, and adapter “A” with the gene-
specific reverse primer.
Amplicon and library preparation
Fusion primers with Roche/454 adapters, MIDs, and
gene-specific sequences were generated [Additional file
1: Table S3] and used to amplify PCR products using
Phusion High-Fidelity DNA polymerase (New England
Biolabs, Ipswich, MA) as previously described [24]. PCR
products were purified with SPRI Ampure-XP paramag-
netic beads (Beckman Coulter Genomics, Danvers, MA).
DNA concentrations were normalized, and products
were pooled into a single amplicon library. Due to the
different sizes of our pooled amplicons, and the
expected number of alleles sequenced, the three ampli-
cons (HLA-1, HLA-2 and DRB amplicon) were pooled
at a 3:6:1 ratio.
Roche/454 Pyrosequencing
Emulsion PCR and pyrosequencing were performed with
the amplicon (Lib-A) kit with GS Junior reagents from
Roche/454 using standard, manufacturer provided pro-
tocols (454 Life Sciences, Branford, CT). An input DNA
molecule-to-bead ratio of 1.5 was used. DNA bead en-
richment levels were expected (between 5 and 20%) for
all experiments, and sequencing yielded >70,000 filter-
pass reads per GS Junior run.
Novel allele Sanger sequencing
One novel allele identified in sample KTS02 was con-
firmed through the use of Sanger sequencing. Primers
specific to the novel allele (and not to the other alleles
present in this individual) were used to amplify a primary
PCR product from previously generated cDNA using High
Fidelity Platinum Taq (Invitrogen, Carlsbad, CA). Products
were purified with SPRI Ampure-XP paramagnetic beads,
and sequenced on an Applied Biosystems 3730xl capillary
sequencer (Applied Biosystems, Carlsbad, CA) using six
different sequencing primers. Data was analyzed, and the
novel SNP confirmed using CodonCode Aligner (Codon-
Code Corporation, Dedham, MA).
Alignment algorithm, matrix creation and Galaxy
implementation
After standard read filtering using the Roche/454 Run-
Processor software, the primary sff file was parsed by
MID and amplicon sequence using the sfffile utility (454
Life Sciences, Branford, CT). Individual sff files were
converted into fastq files using BioPerl, and then submit-
ted to a local Galaxy server for further analysis using the
Galaxy API to write a data library and recursively exe-
cute mapping workflows using Perl and Python. Reads
were quality- and length-filtered to a standardized length
(between 300 and 350 bp depending on amplicon/read
direction) and then mapped to the set of HLA reference
alleles using BLAT [30]. Perfectly matching sequences
were grouped, and matched alleles from each read direc-
tion were joined as described in the Results section.
Positive allele rows were exported using a custom Gal-
axy tool, and the entire specific Galaxy workflow used is
provided Additional file 2: File 1. The resulting matrix of
allele matches was compared to expected match patterns
to establish genotype. In some cases of low read
numbers, potential homozygous loci, or novel alleles,
manual interrogation of individual reads was necessary.
RNA samples with poor amplifications or aberrantly
sequenced reads were excluded from analysis.
Additional files
Additional file 1: Table S1. In silico model of typing resolution for
standard SBT genotyping assays which assess exons 2,3, exons 2,3,4 (class
I) or exon 2 (DRB). Table S2 - Primer sequences used for additional HLA
class II loci typing. Table S3 - Primers used. Table S4 - Read numbers
recovered per sample and amplicon in both genotyping experiments.
Table S5 - Read numbers recovered per sample and amplicon in
preliminary class II additional loci experiment. Table S6 - Class I
genotyping results from the second experiment. Table S7 - DRB
genotyping results from the second experiment. Table S8 - Additional
class II amplicon genotyping results. Table S9 - Primers used for Sanger
sequencing of novel KTS02 HLA-C allele. Table S10 - Cost estimate for
cSBT at a variety of multiplexing levels.
Additional file 2: File 1. Galaxy workflow and custom tools/scripts
used (zip archive).
Additional file 3: File 2. Novel sequences identified during
sequencing (fasta file).
Additional file 4: Figure 1. Formation of abortive, short DNA products
during emPCR.
Abbreviations
HLA: Human Leukocyte Antigen; BLAT: BLAST-like Alignment Tool;
SBT: Sequence-Based Typing; cSBT: cDNA Sequence-Based Typing;
cDNA: complementary DNA; MID: Multiplex IDentifier; IMGT: International
ImMunoGeneTics information system; PCR: Polymerase Chain Reaction;
SSP: Sequence-Specific Primer assay; SSO: Sequence-Specific Oligonucleotide
assay; SNP: Single Nucleotide Polymorphism; SPRI: Solid Phase Reversible
Immobilization; emPCR: emulsion PCR; HIV: Human Immunodeficiency Virus.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SL designed the assay, experiments and analysis pipeline; participated in
assay experiments; analyzed the data; and drafted the manuscript. BG carried
out the assay experiments and assisted in data analysis. HC carried out
confirmatory sequencing experiments. RW participated in experimental
design troubleshooting and manuscript preparation. DK, VB,and ER provided
samples and externally validated genotyping results. DO conceived of the
study, participated in its design, helped draft the manuscript, and oversaw
the project. All authors read and approved the final manuscript.
Acknowledgements
Work at UW-Madison was supported in part by University of Wisconsin
Foundation-Wisconsin Partnership-Medical Education and Research
Committee grant number 20070709. Work at Dana Farber was supported by
grant NIH-U01 A190043. Additional funding was provided by an award from
Lank et al. BMC Genomics 2012, 13:378 Page 12 of 13
http://www.biomedcentral.com/1471-2164/13/378the NIH, distributed by the Human Immunology Project Consortium, number
4 U01 AI08959-02.
Author details
1Wisconsin National Primate Research Center, University of
Wisconsin-Madison, Madison, WI, USA.
2Cancer Vaccine Center, DanaFarber
Cancer Institute, Boston, MA, USA.
3Department of Medicine, Harvard Medical
School, Boston, MA, USA.
4Department of Pathology and Laboratory
Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Received: 23 December 2011 Accepted: 7 July 2012
Published: 6 August 2012
References
1. Caillat-Zucman S: Molecular mechanisms of HLA association with
autoimmune diseases. Tissue Antigens 2009, 73:1–8.
2. Capittini C, Martinetti M, Cuccia M: MHC variation, mate choice and
natural selection: the scent of evolution. Riv Biol 2008, 101:463–480.
3. Kulpa DA, Collins KL: The emerging role of HLA-C in HIV-1 infection.
Immunology 2011, 134:116–122.
4. Rodriguez-Novoa S, Cuenca L, Morello J, Cordoba M, Blanco F, Jimenez-
Nacher I, Soriano V: Use of the HCP5 single nucleotide polymorphism to
predict hypersensitivity reactions to abacavir: correlation with HLA-
B*5701. J Antimicrob Chemother 2010, 65:1567–1569.
5. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A,
Hofstaedter F, Hartmann A: Association of HLA class I antigen
abnormalities with disease progression and early recurrence in prostate
cancer. Cancer Immunol Immunother 2010, 59:529–540.
6. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG: The IMGT/
HLA database. Nucleic Acids Res 2011, 39:D1171–D1176.
7. Balazs I, Beekman J, Neuweiler J, Liu H, Watson E, Ray B: Molecular typing
of HLA-A, -B, and DRB using a high throughput micro array format. Hum
Immunol 2001, 62:850–857.
8. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S,
Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D,
Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J,
Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw
A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y et al; The major genetic
determinants of HIV-1 control affect HLA class I peptide presentation.
Science 2010, 330:1551–1557.
9. Marsh SG: Nomenclature for factors of the HLA system, update June
2011. Tissue Antigens 2011, 78:314–319.
10. Liao WW, Arthur JW: Predicting Peptide binding affinities to MHC
molecules using a modified semi-empirical scoring function. PLoS One
2011, 6:e25055.
11. Friedrich D, Jalbert E, Dinges WL, Sidney J, Sette A, Huang Y, McElrath MJ,
Horton H: Vaccine-induced HIV-specific CD8+ T cells utilize preferential
HLA alleles and target specific regions of HIV-1. J Acquir Immune Defic
Syndr 2011.
12. Greene JM, Wiseman RW, Lank SM, Bimber BN, Karl JA, Burwitz BJ, Lhost JJ,
Hawkins OE, Kunstman KJ, Broman KW, Wolinsky SM, Hildebrand WH,
O'Connor DH: Differential MHC class I expression in distinct leukocyte
subsets. BMC Immunol 2011, 12:39.
13. Kim OY, Monsel A, Bertrand M, Coriat P, Cavaillon JM, Adib-Conquy M:
Differential down-regulation of HLA-DR on monocyte subpopulations
during systemic inflammation. Crit Care 2010, 14:R61.
14. Khanna R, Silins SL, Weng Z, Gatchell D, Burrows SR, Cooper L: Cytotoxic T
cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr
virus epitope: influence of peptide conformation and TCR-peptide
interaction. Eur J Immunol 1999, 29:1587–1597.
15. Parham P: MHC class I molecules and KIRs in human history, health and
survival. Nat Rev Immunol 2005, 5:201–214.
16. Sampah ME, Ceccato CM, Blankson JN: HIV type 1-mediated
downregulation of HLA-B*57/B*5801 proteins on elite suppressor CD4+
T cells. AIDS Res Hum Retroviruses 2011, 27:183–186.
17. Kloverpris HN, Stryhn A, Harndahl M, van der Stok M, Payne RP, Matthews
PC, Chen F, Riddell L, Walker BD, Ndung'u T, Buus S, Goulder P: HLA-B*57
Micropolymorphism shapes HLA allele-specific epitope immunogenicity,
selection pressure, and HIV immune control. J Virol 2012, 86:919–929.
18. Lebedeva TV, Mastromarino SA, Lee E, Ohashi M, Alosco SM, Yu N:
Resolution of HLA class I sequence-based typing ambiguities by group-
specific sequencing primers. Tissue Antigens 2011, 77:247–250.
19. Bettencourt BF, Santos MR, Fialho RN, Couto AR, Peixoto MJ, Pinheiro JP,
Spinola H, Mora MG, Santos C, Brehm A, Bruges-Armas J: Evaluation of two
methods for computational HLA haplotypes inference using a real
dataset. BMC Bioinformatics 2008, 9:68.
20. Listgarten J, Brumme Z, Kadie C, Xiaojiang G, Walker B, Carrington M,
Goulder P, Heckerman D: Statistical resolution of ambiguous HLA typing
data. PLoS Comput Biol 2008, 4:e1000016.
21. Nunes JM, Riccio ME, Tiercy JM, Sanchez-Mazas A: Allele frequency
estimation from ambiguous data: using resampling schema in validating
frequency estimates and in selective neutrality testing. Hum Biol 2011,
83:437–447.
22. Bentley G, Higuchi R, Hoglund B, Goodridge D, Sayer D, Trachtenberg EA,
Erlich HA: High-resolution, high-throughput HLA genotyping by next-
generation sequencing. Tissue Antigens 2009, 74:393–403.
23. Erlich RL, Jia X, Anderson S, Banks E, Gao X, Carrington M, Gupta N, DePristo
MA, Henn MR, Lennon NJ, de Bakker PI: Next-generation sequencing for
HLA typing of class I loci. BMC Genomics 2011, 12:42.
24. Lank SM, Wiseman RW, Dudley DM, O'Connor DH: A novel single cDNA
amplicon pyrosequencing method for high-throughput, cost-effective
sequence-based HLA class I genotyping. Hum Immunol 2010, 71:1011–1017.
25. Korlach J, Bjornson KP, Chaudhuri BP, Cicero RL, Flusberg BA, Gray JJ,
Holden D, Saxena R, Wegener J, Turner SW: Real-time DNA sequencing
from single polymerase molecules. Methods Enzymol 2010, 472:431–455.
26. Min SK, Kim WY, Cho Y, Kim KS: Fast DNA sequencing with a graphene-
based nanochannel device. Nat Nanotechnol 2011, 6:162–165.
27. Gilles A, Meglecz E, Pech N, Ferreira S, Malausa T, Martin JF: Accuracy and
quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC
Genomics 2011, 12:245.
28. Holcomb CL, Hoglund B, Anderson MW, Blake LA, Bohme I, Egholm M,
Ferriola D, Gabriel C, Gelber SE, Goodridge D, Hawbecker S, Klein R, Ladner
M, Lind C, Monos D, Pando MJ, Proll J, Sayer DC, Schmitz-Agheguian G,
Simen BB, Thiele B, Trachtenberg EA, Tyan DB, Wassmuth R, White S, Erlich
HA: A multi-site study using high-resolution HLA genotyping by next
generation sequencing. Tissue Antigens 2011, 77:206–217.
29. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M,
Nekrutenko A, Taylor J: Galaxy: a web-based genome analysis tool for
experimentalists. Curr Protoc Mol Biol 2010, 19:1–21.
30. Kent WJ: BLAT–the BLAST-like alignment tool. Genome Res 2002, 12:656–664.
31. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA,
Fernandez-Vina M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW,
Mach B, Maiers M, Mayr WR, Muller CR, Parham P, Petersdorf EW, Sasazuki T,
Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J:
Nomenclature for factors of the HLA system, 2010. Tissue Antigens 2010,
75:291–455.
32. Koehler RN, Walsh AM, Sanders-Buell EE, Eller LA, Eller M, Currier JR, Bautista
CT, Wabwire-Mangen F, Hoelscher M, Maboko L, Kim J, Michael NL, Robb
ML, McCutchan FE, Kijak GH: High-throughput high-resolution class I HLA
genotyping in East Africa. PLoS One 2010, 5:e10751.
33. Keskin DB, Reinhold B, Lee SY, Zhang G, Lank S, O'Connor D, Berkowitz RS,
Brusic V, Kim SJ, Reinherz EL: Direct identification of an HPV-16 tumor
antigen from cervical cancer biopsy specimens. Frontiers in Immunology
2011, 2.
34. Edgar RC: MUSCLE: a multiple sequence alignment method with reduced
time and space complexity. BMC Bioinformatics 2004, 5:113.
doi:10.1186/1471-2164-13-378
Cite this article as: Lank et al.: Ultra-high resolution HLA genotyping and
allele discovery by highly multiplexed cDNA amplicon pyrosequencing.
BMC Genomics 2012 13:378.
Lank et al. BMC Genomics 2012, 13:378 Page 13 of 13
http://www.biomedcentral.com/1471-2164/13/378